Trial Profile

A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African Children

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Measles and rubella virus vaccine (Primary) ; Poliovirus vaccine (Primary) ; R 21 (Primary) ; Yellow fever vaccine (Primary)
Indications Malaria
Focus Adverse reactions; Pharmacodynamics

17 Sep 2025 Status changed from active, no longer recruiting to completed.
15 May 2024 Planned End Date changed from 1 Aug 2024 to 1 May 2025.
15 May 2024 Planned primary completion date changed from 1 Sep 2023 to 1 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com